Evidence map›Paper›PMID 41615188›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Endocytic Control of Cell-Autonomous and Non-Cell-Autonomous Functions of p53.

Roberta Cacciatore, Andrea Basile, Stefano Freddi, Irene Schiano Lomoriello, Carlo Ribelle Zucca, Giuseppe Ciossani, Luigi Scietti, Alessandro Cuomo, Simona Ronzoni, Simone Pelicci and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Roberta CacciatoreIEO, European Institute of Oncology IRCCS, Milan, Italy.
Andrea BasileIEO, European Institute of Oncology IRCCS, Milan, Italy.
Stefano FreddiIEO, European Institute of Oncology IRCCS, Milan, Italy.
Irene Schiano LomorielloIEO, European Institute of Oncology IRCCS, Milan, Italy.
Carlo Ribelle ZuccaIEO, European Institute of Oncology IRCCS, Milan, Italy.
Giuseppe CiossaniIEO, European Institute of Oncology IRCCS, Milan, Italy.
Luigi SciettiIEO, European Institute of Oncology IRCCS, Milan, Italy.
Alessandro CuomoIEO, European Institute of Oncology IRCCS, Milan, Italy.
Simona RonzoniIEO, European Institute of Oncology IRCCS, Milan, Italy.
Simone PelicciIEO, European Institute of Oncology IRCCS, Milan, Italy.
Mario FarettaIEO, European Institute of Oncology IRCCS, Milan, Italy.
Elena ZaccheroniIEO, European Institute of Oncology IRCCS, Milan, Italy.
Giuliana PelicciIEO, European Institute of Oncology IRCCS, Milan, Italy.
Vittoria MataforaIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Angela BachiIFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
Rosalind Helen GunbyIEO, European Institute of Oncology IRCCS, Milan, Italy.
Salvatore PeceIEO, European Institute of Oncology IRCCS, Milan, Italy.
Sara SigismundIEO, European Institute of Oncology IRCCS, Milan, Italy.
Letizia LanzettiDepartment of Oncology, University of Torino Medical School, Torino, Italy.
Ivan Nicola ColalucaIEO, European Institute of Oncology IRCCS, Milan, Italy.
Pier Paolo Di FioreIEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID https://orcid.org/0000-0002-2252-0950

Funding

Associazione Italiana per la Ricerca sul Cancro IG #22811Associazione Italiana per la Ricerca sul Cancro IG #23060Associazione Italiana per la Ricerca sul Cancro IG #24415Associazione Italiana per la Ricerca sul Cancro IG #27014Associazione Italiana per la Ricerca sul Cancro IG #31110European Research Council #101002280European Research Council ERC-CoG2020Italian Ministry of University and Scientific Research PRIN 2020 Prot. 2020R2BP2EItalian Ministry of University and Scientific Research PRIN 2022 Prot. 2022W93FTWNational Center for Gene Therapy and Drugs based on RNA TechnologyNext Generation EU-CN00000041The Italian Ministry of Health: Ricerca Corrente 2023-2024 and 5 per 1000 funds PNRR-MCNT2-2023-12378490The Italian Ministry of Health: Ricerca Corrente 2023-2024 and 5 per 1000 funds RF-2021-12373957
6 · The paper itself

Abstract

NUMB is an endocytic protein with tumor suppressor activity, largely mediated by its ability to inhibit p53 degradation. This function depends on the inclusion of a short alternatively spliced exon (Ex3) in NUMB, although the mechanistic link between endocytosis and p53 regulation remains unclear. Here, we show that the Ex3-encoded sequence directs NUMB to the plasma membrane, where it forms a complex with the endocytic adaptor SNX9. This complex recruits p53 in an SNX9-dependent manner and is internalized and trafficked to multivesicular bodies, culminating in exosomal secretion, in a process requiring both SNX9 and NUMB. Exosomal p53 is taken up by recipient cells and translocated to the nucleus, where it activates p53-dependent transcriptional and phenotypic programs. These findings suggest that exosome-mediated p53 transfer may contribute to the establishment of a tumor-suppressive microenvironment.

Indexed as

EndocytosisMembrane ProteinsNerve Tissue ProteinsSorting NexinsTumor Suppressor Protein p53Alternative SplicingAnimalsCell MembraneExosomesHumansMembrane ProteinsNerve Tissue ProteinsNUMB protein, humanSorting NexinsTumor Suppressor Protein p53exosomesnon‐cell‐autonomousNUMBp53SNX9

Identifiers

PMID41615188
PMCPMC13248759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.